Gilead Sciences Inc

GILD: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|?@LOCK|R$LOCK|$vndqR

Gilead Earnings: Low Tariff Exposure and Lenacapavir Filing On Track

Gilead reported flat first-quarter 2025 revenue and cost discipline supported a mid-single-digit decline in operating expenses. Management's product sales and non-GAAP diluted EPS guidance for 2025 remain unchanged.

Sponsor Center